PE122699A1 - Antagonistas de receptores de vitronectina - Google Patents

Antagonistas de receptores de vitronectina

Info

Publication number
PE122699A1
PE122699A1 PE1998000881A PE00088198A PE122699A1 PE 122699 A1 PE122699 A1 PE 122699A1 PE 1998000881 A PE1998000881 A PE 1998000881A PE 00088198 A PE00088198 A PE 00088198A PE 122699 A1 PE122699 A1 PE 122699A1
Authority
PE
Peru
Prior art keywords
alkyl
refers
compound
receptor antagonists
halo
Prior art date
Application number
PE1998000881A
Other languages
English (en)
Inventor
William H Miller
William E Bondinell
Dirk Heerding
James M Samanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE122699A1 publication Critical patent/PE122699A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES CH2 u O; R1 ES H, HALO, ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6, CH2NR"R"; X ES O o CH2; Y ES UN GRUPO a, b, c; G ES NR", S, O; R` ES H, ALQUILO C1-C6, O-ALQUILO C1-C6, S-ALQUILO C1-C6, NR"R", HALO; R" ES H, ALQUILO C1-C6; s ES 0-2. UN COMPUESTO PREFERIDO ES ACIDO (+/-)-10,11-DIHIDRO-3-[2-(6-AMINOPIRIDIN-2-IL)-1-ETOXI]-5H-DIBENZO[a,d]CICLOHEPTENO-10-ACETICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS UN AGENTE ANTINEOPLASICO TAL COMO TOPOTECAN, CISPLATIN. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN ANTAGONISTA DEL RECEPTOR OVß3 POR LO QUE PUEDE SER UTIL PARA TRATAR OSTEOPOROSIS, ANGIOGENESIS, INHIBIR EL CRECIMIENTO TUMORAL O LA METASTASIS TUMORAL, ATEROSCLEROSIS, RESTENOSIS, INFLAMACION
PE1998000881A 1997-09-19 1998-09-16 Antagonistas de receptores de vitronectina PE122699A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5934297P 1997-09-19 1997-09-19
US6343897P 1997-10-29 1997-10-29

Publications (1)

Publication Number Publication Date
PE122699A1 true PE122699A1 (es) 2000-02-12

Family

ID=26738652

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000881A PE122699A1 (es) 1997-09-19 1998-09-16 Antagonistas de receptores de vitronectina

Country Status (26)

Country Link
EP (1) EP1025090A4 (es)
JP (1) JP2001517658A (es)
KR (1) KR20010024141A (es)
CN (1) CN1278250A (es)
AP (1) AP2000001766A0 (es)
AR (1) AR015446A1 (es)
AU (1) AU738433B2 (es)
BG (1) BG104314A (es)
BR (1) BR9812340A (es)
CA (1) CA2303487A1 (es)
CO (1) CO5011087A1 (es)
DZ (1) DZ2609A1 (es)
EA (1) EA200000336A1 (es)
HU (1) HUP0003641A3 (es)
ID (1) ID24162A (es)
IL (1) IL135028A0 (es)
MA (1) MA26547A1 (es)
NO (1) NO20001407L (es)
NZ (1) NZ503389A (es)
OA (1) OA11341A (es)
PE (1) PE122699A1 (es)
PL (1) PL339381A1 (es)
SK (1) SK4082000A3 (es)
TR (1) TR200000721T2 (es)
TW (1) TW513303B (es)
WO (1) WO1999015508A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR
DE19936780A1 (de) * 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
US6881736B1 (en) 1999-09-07 2005-04-19 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2004503540A (ja) 2000-06-15 2004-02-05 ファルマシア・コーポレーション インテグリンアンタゴニストとして有用なジヒドロスチルベンアルカン酸誘導体
ES2259047T3 (es) * 2000-10-24 2006-09-16 MERCK & CO., INC. Antagonista de receptor de integrina de la dibenzoxazepina.
AU2002316855B2 (en) 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
WO2008087025A2 (en) 2007-01-18 2008-07-24 Merck Patent Gmbh Specific therapy and medicament using integrin ligands for treating cancer
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
RU2016146826A (ru) 2014-05-30 2018-07-04 Пфайзер Инк. Производные карбонитрилов как селективные модуляторы андрогенового рецептора
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH443281A (de) * 1964-02-18 1967-09-15 Hoffmann La Roche Verfahren zur Herstellung von Dibenzocycloheptatrienverbindungen
US3335148A (en) * 1966-02-17 1967-08-08 Lilly Co Eli 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof
US5698551A (en) * 1995-04-07 1997-12-16 Novo Nordisk A/S Heterocyclic compounds
SI0910563T1 (en) * 1995-06-29 2003-10-31 Smithkline Beecham Corporation Integrin receptor antagonists
US5659033A (en) * 1995-09-13 1997-08-19 Neurogen Corporation N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin

Also Published As

Publication number Publication date
NZ503389A (en) 2002-03-28
DZ2609A1 (fr) 2003-03-01
AR015446A1 (es) 2001-05-02
EA200000336A1 (ru) 2000-10-30
EP1025090A4 (en) 2000-11-08
EP1025090A1 (en) 2000-08-09
JP2001517658A (ja) 2001-10-09
NO20001407D0 (no) 2000-03-17
MA26547A1 (fr) 2004-12-20
OA11341A (en) 2003-12-10
AP2000001766A0 (en) 1998-09-18
KR20010024141A (ko) 2001-03-26
TW513303B (en) 2002-12-11
AU738433B2 (en) 2001-09-20
ID24162A (id) 2000-07-13
NO20001407L (no) 2000-03-17
CN1278250A (zh) 2000-12-27
CO5011087A1 (es) 2001-02-28
BR9812340A (pt) 2001-12-18
SK4082000A3 (en) 2000-09-12
IL135028A0 (en) 2001-05-20
AU9397298A (en) 1999-04-12
PL339381A1 (en) 2000-12-18
TR200000721T2 (tr) 2000-11-21
BG104314A (en) 2001-01-31
CA2303487A1 (en) 1999-04-01
HUP0003641A3 (en) 2002-10-28
HUP0003641A2 (en) 2001-03-28
WO1999015508A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
PE122699A1 (es) Antagonistas de receptores de vitronectina
UA74391C2 (uk) Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти
NZ336560A (en) 10,11-dihydro-3-[substituted pyridyl-1-alkoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid derivatives useful as vitronectin receptor antagonists
BRPI0116237B8 (pt) "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
BR9916790A (pt) Uso de um composto, composto, processo para amanufatura do mesmo, composição farmacêtica, e,método para produzir um efeito de dano vascularem um animal de sangue quente
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
ATE219659T1 (de) Verwendung gelierbarer pharmazeutischer zusammensetzungen in der parodontologie
ES2187675T3 (es) (metilsulfonil)fenil-2-(5h)-furanonas como inhibidores de cox-2.
HK1048469A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ES2194223T3 (es) Antagonistas de la integrina.
PT894084E (pt) Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
ATE249213T1 (de) Pentafluorobenzensulfonamiden und analoge
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
BR9408325A (pt) Composto composição farmacêutica e processo para a manufatura de um composto
ATE327748T1 (de) Alkandiol derivate zur behandlung von knochenkrankheiten
PE20001563A1 (es) Antagonistas del receptor de vitronectina
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
WO2002022616A3 (en) Alpha v integrin receptor antagonists
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
PE20010582A1 (es) Antagonistas de los receptores de vitronectina
AR026839A1 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FC Refusal